Share Name Share Symbol Market Type Share ISIN Share Description
Constellation Healthcare Technologies LSE:CHT London Ordinary Share USU210051004 CMN SHS USD0.0001 (DI/REG S)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 169.00p 165.00p 173.00p 169.00p 169.00p 169.00p 228 07:30:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 52.1 7.7 7.5 20.0 149.38

Constellation Healthcare (CHT) Latest News

More Constellation Healthcare News
Constellation Healthcare Takeover Rumours

Constellation Healthcare (CHT) Share Charts

1 Year Constellation Healthcare Chart

1 Year Constellation Healthcare Chart

1 Month Constellation Healthcare Chart

1 Month Constellation Healthcare Chart

Intraday Constellation Healthcare Chart

Intraday Constellation Healthcare Chart

Constellation Healthcare (CHT) Discussions and Chat

Constellation Healthcare Forums and Chat

Date Time Title Posts
26/9/201611:29Constellation Healthcare Technologies667
03/3/201021:24Company Health Group220
03/3/201008:53****** CHARTS ******10
08/10/200719:47Company Health Group - The New Name In Town.188
26/8/200612:03Company Health with Charts & News1

Add a New Thread

Constellation Healthcare (CHT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
27/09/2016 12:34:48169.00228385.32O
View all Constellation Healthcare trades in real-time

Constellation Healthcare (CHT) Top Chat Posts

DateSubject
27/9/2016
09:20
Constellation Healthcare Daily Update: Constellation Healthcare Technologies is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker CHT. The last closing price for Constellation Healthcare was 169p.
Constellation Healthcare Technologies has a 4 week average price of 159.98p and a 12 week average price of 148.28p.
The 1 year high share price is 180p while the 1 year low share price is currently 122.50p.
There are currently 88,390,749 shares in issue and the average daily traded volume is 174,692 shares. The market capitalisation of Constellation Healthcare Technologies is £149,380,365.81.
23/9/2016
08:23
rivaldo: Agreed. This is a very good, earnings-enhancing - and large - acquisition, which will add almost $8m EBITDA at a cost of just $24m assuming the synergies come about, which they surely will given what's been achieved to date. The only quibbles are the share price used, which as bb2 says presumably relate to the date that negotiations commenced given the share price just three weeks ago, and the CEO's convertible loan at 7.5% with an undefined conversion price. The benefits of the deal in earnings enhancement terms are certainly persuasive overall. Forecasts for next year will probably increase from 18.84p EPS now I'd have thought.
12/9/2016
17:01
loobrush: Excellent-bought in after results-looked to me way to cheap and believed that the company is one in the right place at the right time and could grow and grow in a wide open market. I also think that the profits could grow faster than turnover as they benefit from economies of scale. I often find that with some companies that issue great results that the share price hardly moves for a week or two, then starts rising. I think this is due to Funds taking time to to analyse data thoroughly before buying, which can then give rise to a significant share price increase. Time will tell.
02/9/2016
12:07
rivaldo: Stifel are joint brokers to CHT. They last had a 271p target price, but I haven't seen anything from them since this in October last year - anyone got anything more recent from them? http ://www.proactiveinvestors.co.uk/companies/news/116101/constellation-healthcare-s-rating-too-modest-says-stifel-116101.html "Broker Stifel has initiated coverage of Constellation Healthcare Technologies (LON:CHT) with a ‘buy’ rating and 271p a share price target. The stock would have to advance around 70% from today’s levels to match that valuation. Constellation describes itself as an RCM, or a revenue cycle management company. Essentially, what it does for the nearly 6,000 doctors on its books is bill and collect monies owed by government, insurers and patients. It also provides practice management and purchasing services. Obamacare (or the Affordable Care Act to give it its proper name), has created huge upheaval for physicians, complicating the rules on payment while forcing down remuneration. For the barely profitable small firms carrying out mission-critical billing operations, Obamacare adds a financially onerous level of bureaucracy that is often the final straw. For Constellation, it has whipped up the perfect storm – or at the very least a great backdrop to consolidate a highly fragmented market. Last month it made two acquisitions in a month at a total cost of US$32mln. Meanwhile in March it completed its biggest deal to date with the purchase of New York-based Physicians Practice Plus for US$20mln. Stifel’s Ken Rumph estimates that, including the contribution of the new businesses, Constellation trading on a very modest enterprise multiple of just 4.5 times and a price to earnings multiple of 10 times. “Constellation is rolling up a large, growing, sticky and fragmented market for revenue cycle (billing) management in the USA,” said Stifel analyst Rumph. "
02/9/2016
08:39
adamb1978: Saucepan: Regarding your question: "I think I have now learned not to invest in US companies listed on AIM. What is it that does not pass muster and prevents them from listing in their home country with a much bigger investor and funding base?" Are you familiar with NYSE and Nasdaq listing rules? CHT and other companies like SOM wouldnt meet the listing requirements. Nasdaq rules are quite stringent and include things such as minimum market cap (and/or share price), 3 years of profitability etc Adam
02/9/2016
07:41
johnwise: De-rampers your posts are not up to the required standard Revenue Increased by 78% to $57.0M ($32.0M in 2015) · 22% organic growth in the RCM business · Cash from Operations increased by 19% to $10.9M ($4.2M in 2015) · Debt facility paid down in full from internal cash generation · 10,000+ US Physicians currently being serviced · RCM business revenue increased by 110% to $43.6M ($20.7M in 2015) · RCM EBITDA increased by 139% to $16.8M ($7.0M in 2015) http://uk.advfn.com/stock-market/london/constellation-healthcare-CHT/share-news/Constellation-Healthcare-Tech-Inc-Interim-Results/72343953
22/8/2016
15:02
rivaldo: Surprising given that the 15.22p EPS forecast in the thread header remains the forecast despite the fall in the pound against the dollar, which should improve the results in pure translation terms. And also given that we know that H1 trading was good from the trading statement, so next month's results should lead to a share price boost. Volumes are tiny, so I suspect it's just summer drift - any interest at ball prior to the results could lead to a good bounce back due to CHT's illiquidity, as it did recently.
21/7/2016
12:27
rivaldo: Cheers Santangello, and welcome. Nice 25,000 share buy from yesterday just reported late. The share price should now climb steadily in the run-up to the interims in mid-September - and we may also get an acquisition or two before that if all goes well (last year there were two acquisitions in September).
23/5/2016
14:54
dave2608: Rivaldo But they were all sells, just under £2 million's worth, which logic would tell you creates an overhang not diminishes one and the share price doesn't budge. Then about £27k's worth of buys and the share price tick upwards. Weird, I just don't get it. The only thing I can think of is that the shares are being sold by one large investor/investors to be immediately bought by another large investor. If this isn't the case, there must be some other plausible explanation. Perhaps someone can enlighten me.
24/3/2016
13:50
rivaldo: Nice summary here: http ://www.proactiveinvestors.co.uk/companies/news/124013/constellation-healthcare-technologies-inc-s-plan-pays-off-124013.html "Constellation Healthcare Technologies Inc's plan pays off 16:42 23 Mar 2016 Constellation Healthcare Technologies’ buy and build strategy certainly appears to be working. Constellation Healthcare Technologies’ (LON:CHT) buy and build strategy certainly appears to be working, judging by the annual results statement. Revenues rose 40% to US$76.7mln in the 12 months ended last December, giving growth in underlying profits (EBITDA) of US$16.1mln, uo 115%. Conversion of those profits into cash was good as money it made from operations rose 91% to US$15.5mln. The layering on of new businesses masked a strong underlying growth rate of 8.8%. Constellation describes itself as an RCM, or a revenue cycle management company. Essentially, what it does for more than 9,000 doctors on its books is bill and collect monies owed by government, insurers and patients. It also provides practice management and purchasing services. Consolidation play Obamacare, or the Affordable Care Act to give it its proper name, has created huge upheaval for physicians, complicating the rules on payment while forcing down remuneration. For the barely profitable small firms carrying out mission-critical billing operations, Obamacare adds a financially onerous level of bureaucracy that is often the final straw. For Constellation, it has whipped up the perfect storm – or at the very least a great backdrop - against which to consolidate a highly fragmented market. In December the company unveiled its fourth deal of a fairly short life as a stock market-quoted company when it paid US$30mln for MDRX Medical Billing. Talking about full-year results, chief executive Paul Parmar said: "Constellation enjoyed a successful year across all metrics. “We increased our revenue base and more importantly, significantly increased our profitability for the year. “Our acquisition and integration strategy is proven and we are quickly becoming one of the largest healthcare and technology services businesses in the US.” finnCap’s punchy price target The broker reckons the stock is worth 310p more than double the closing share price. It points out the business is trading on a forward multiple of less than 10 times earnings 8%-plus free cash flow."
19/1/2016
09:46
rivaldo: CHT were featured in this weekend's FT via the Director Deals section as follows: Http://www.ft.com/cms/s/0/c7251d3c-bac7-11e5-b151-8e15c9a029fb.html#axzz3xMZrq35O "Parmar sees Constellation as a star The capital requirements of Aim-listed US buy-and-build medical billings group Constellation Healthcare Technologies apparently know no ends. For retail investors, this comes with dilution and a largely static share price. The good news is that the money is being used just as Constellation promised, to acquire “mom-and-pop” outfits in the fragmented $37bn (£25.7bn) revenue cycle management industry. Encouragingly, chief executive and majority owner Paul Parmar has repeatedly coughed up for those deals. He recently subscribed for £2.65m worth of new shares in a £30m placing partly to fund the purchase of Ohio-based hospital practice management group MDRX. Mr Parmar was joined by new and existing shareholders, including financial director Sam Zaharis and Capita founder and non-executive director Sir Rodney Aldridge. Broker FinnCap expects adjusted pre-tax profit and earnings per share of $30.3m and 21.7¢ this calendar year, up from $15.6m and 15.6¢ in 2015. Buy."
Constellation Healthcare share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20160928 05:11:46